Order Article Reprints

Dimou M, Fioretzaki R, Zerzi C, Konstantinou E, Asimakopoulos JV, Arapaki M, Piperidou A, Machairas A, Kopsaftopoulou A, Liaskas A, et al. Venetoclax–Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview. Cancers. 2025; 17(19):3159. https://doi.org/10.3390/cancers17193159

Dimou, Maria, Rodanthi Fioretzaki, Calliope Zerzi, Eliana Konstantinou, John V. Asimakopoulos, Maria Arapaki, Alexia Piperidou, Alexandros Machairas, Anastasia Kopsaftopoulou, Athanasios Liaskas, and et al. 2025. "Venetoclax–Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview" Cancers 17, no. 19: 3159. https://doi.org/10.3390/cancers17193159

Dimou, M., Fioretzaki, R., Zerzi, C., Konstantinou, E., Asimakopoulos, J. V., Arapaki, M., Piperidou, A., Machairas, A., Kopsaftopoulou, A., Liaskas, A., Bitsani, A., Belia, M., Panitsas, F., Benekou, A., Petsa, P., Plata, E., Tsaftaridis, P., Siakantaris, M., Vassilakopoulos, T. P., ... Angelopoulou, M. K. (2025). Venetoclax–Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview. Cancers, 17(19), 3159. https://doi.org/10.3390/cancers17193159